N2 year in review and message from the editor to our reviewers

Affiliations

¹ ICREA-IDIBAPS, Hospital Clínic (J.D.), University of Barcelona, Spain; the University of Pennsylvania (J.D, D.L.K.), Philadelphia, PA; the Charite University Hospital (F.P.), Berlin, Germany; and the Department of Neurology (S.S.Z.), University of California, San Francisco, CA.

Editorial

Josep Dalmau et al. Neurol Neuroimmunol Neuroinflamm. 2018.

. 2018 Dec 19;6(1):e525.

doi: 10.1212/NXI.0000000000000525. eCollection 2019 Jan.

¹ ICREA-IDIBAPS, Hospital Clínic (J.D.), University of Barcelona, Spain; the University of Pennsylvania (J.D, D.L.K.), Philadelphia, PA; the Charite University Hospital (F.P.), Berlin, Germany; and the Department of Neurology (S.S.Z.), University of California, San Francisco, CA.

No abstract available

References

1. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med 2018;378:158–168. - PubMed
1. Yshii LM, Hohlfeld R, Liblau RS. Inflammatory CNS disease caused by immune checkpoint inhibitors: status and perspectives. Nat Rev Neurol 2017;13:755–763. - PubMed
1. Williams TJ, Benavides DR, Patrice KA, et al. . Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016;73:928–933. - PubMed
1. Hottinger AF, de Micheli R, Guido V, Karampera A, Hagmann P, Du Pasquier R. Natalizumab may control immune checkpoint inhibitor–induced limbic encephalitis. Neurol Neuroimmunol Neuroinflamm 2018;5:e439. doi: 10.1212/NXI.0000000000000439. - DOI - PMC - PubMed
1. Dalmau J, Graus F. Antibody-mediated encephalitis. N Engl J Med 2018;378:840–851. - PubMed